Trials / Conditions / Glycogen Storage Disease Type II (GSD-II)

Glycogen Storage Disease Type II (GSD-II)

15 registered clinical trials studyying Glycogen Storage Disease Type II (GSD-II) — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease NCT01410890	Genzyme, a Sanofi Company	Phase 4
Completed	Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients. NCT01898364	Genzyme, a Sanofi Company	Phase 1
Terminated	A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Pa NCT01597596	Genzyme, a Sanofi Company	Phase 4
Completed	Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidas NCT01288027	Genzyme, a Sanofi Company	Phase 4
Terminated	Immune Tolerance Induction Study NCT00701701	Genzyme, a Sanofi Company	Phase 4
Completed	Growth and Development Study of Alglucosidase Alfa NCT00486889	Genzyme, a Sanofi Company	Phase 4
Recruiting	Pompe Pregnancy Sub-Registry NCT00567073	Genzyme, a Sanofi Company	—
Completed	High Dose or High Dose Frequency Study of Alglucosidase Alfa NCT00483379	Genzyme, a Sanofi Company	Phase 4
Completed	Late-Onset Treatment Study Extension Protocol NCT00455195	Genzyme, a Sanofi Company	Phase 4
Completed	Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving NCT00731081	Genzyme, a Sanofi Company	—
Completed	Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respirato NCT00268944	Genzyme, a Sanofi Company	Phase 3
Completed	A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-O NCT00158600	Genzyme, a Sanofi Company	Phase 3
Completed	A Study of rhGAA in Patients With Late-Onset Pompe Disease NCT00250939	Genzyme, a Sanofi Company	Phase 2
Completed	Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were P NCT00765414	Genzyme, a Sanofi Company	Phase 2
Approved For Marketing	Alglucosidase Alfa Temporary Access Program NCT00520143	Genzyme, a Sanofi Company	—